EGFR and breast carcinoma: We further demonstrated that the SHP-1–induced suppression of EGFR inactivated the Ras/Erk/GSK3β pathway, thus enhancing understanding of the molecular mechanism of breast cancer progression, given that this pathway is known to be dysregulated in many cancers40–42.